COMMUNIQUÉS West-GlobeNewswire

-
INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies
12/10/2018 -
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia
12/10/2018 -
Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China
12/10/2018 -
Ossur Hf : Q3 2018 Results - Conference call Thursday 25 October at 11:00 CET
12/10/2018 -
Fiasp® is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart
12/10/2018 -
GUERBET : Mise à disposition du Rapport Financier semestriel 2018
12/10/2018 -
Rule 2.9 Announcement
12/10/2018 -
Kiadis Pharma provides regulatory and clinical update on ATIR101
12/10/2018 -
Veritas Pharma Attending CannX International Medical Cannabis Conference in Tel Aviv, Israel
11/10/2018 -
Abattis Bioceuticals Provides Update on Vaporizer Product Line
11/10/2018 -
Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
11/10/2018 -
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
11/10/2018 -
Align Technology Expands Invisalign Interactive Brand Experience Pilot Program to Connect More Consumers With Invisalign Doctors
11/10/2018 -
Integra LifeSciences to Host Third Quarter 2018 Earnings Results Conference Call on October 31, 2018
11/10/2018 -
KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape
11/10/2018 -
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
11/10/2018 -
Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares
11/10/2018 -
Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program
11/10/2018 -
Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA
11/10/2018
Pages